Clinical benefits of early triptan therapy for migraine

Cephalalgia, Supplement

Volumn 24, Issue 2, 2004, Pages 24-30

  Láinez, Miguel J A ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Almotriptan; Early intervention; Migraine; Sustained pain free response

Indexed keywords

ALMOTRIPTAN; ANTIMIGRAINE AGENT; SUMATRIPTAN; ANALGESIC AGENT; ELETRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RIZATRIPTAN; TRIPTAN DERIVATIVE;

CLINICAL TRIAL; CONFERENCE PAPER; DISABILITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MIGRAINE; PAIN ASSESSMENT; PATHOPHYSIOLOGY; SENSITIZATION; SIDE EFFECT; THORAX PAIN; TREATMENT OUTCOME; ALLODYNIA; ARTICLE; CLINICAL EFFECTIVENESS; EARLY INTERVENTION; HEADACHE; PAIN INTENSITY; PATIENT SATISFACTION; RECURRENCE RISK; TIME TO TREATMENT; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 10344234213     PISSN: 08001952     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2004.00895.x     Document Type: Conference Paper

References (21)

1. Láinez JM. Epidemiología e impacto socioeconómico de Ia migraña. In: Pascual J, ed. Migraña. Barcelona: Masson, 2001:1-17.
2. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001; 41:638-45.
3. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41:646-57.
4. Dowson AJ, Massiou H, Laínez JM, Cabarrocas X. Almotriptan improves response rates when treatment is within 1 hour of migraine onset. Headache 2004; 44:318-22.
5. Mathew N. Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache 2003; 43:1075-9.
6. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002; 42:28-31.
7. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 1999; 39 (Suppl. 2):S20-6.
8. Gallagher RM. What do patients want from acute migraine treatment? Cephalalgia 2004; 24 (Suppl. 2):8-15.
9. International Headache Society Clinical Trials Subcommittee. Guidelines for Controlled Trials of Drugs in Migraine, 2nd edn. Cephalalgia 2000; 20:765-86.
10. Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache 2003; 43:36-43.
11. Silberstein SD for the US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. http://www. aan.com/professionals/prac tice/guidelines
12. Goadsby PJ, Lipton RB, Ferrari M. Migraine: current understanding and treatment. N Engl J Med 2002; 346 (4):257-70.
13. 1B/1D agonists) in acute migraine treatment. a meta-analysis of 53 trials. Lancet 2001; 358:1668-75.
14. Cady RK, Lipton RB, Hall C, Stewart WF, O'Quinn S, Gutterman D. Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. Headache 2000; 40:792-7.
15. Burstein R, Collins B, Bajwa Z, Jakubowski M. Triptan therapy can abort attacks if given before the establishment or in the presence of cutaneous allodynia and central sensitization: clinical and preclinical evidence. Headache 2002; 42:389. (Abstract)
16. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack, clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000; 123:1703-9.
17. Silberstein SD. Migraine pathophysiology and its clinical implications. Cephalalgia 2004; 24 (Suppl. 2):2-7.
18. Dowson AJ, Massiou H, Láinez JM, Cabarrocas X. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomised, double-blind, placebo-controlled clinical trial. Cephalalgia 2002; 22:453-61.
19. Pascual J, Láinez JM, Leira R, Titus F, Mateos V, Galván J. Almotriptan in the treatment of migraine attacks in clinical practice: results of the TEA 2000 observational study. Neurologia 2003; 18:7-17.
20. Pascual J, Tranche S, Leira R, Láinez JM, Mateos V, Galvan J. Almotriptan in clinical practice: experience in primary care vs neurology setting. Headache 2003; 43:525. (Abstract)
21. Láinez JM, Pascual J, Mateos V, Galván J. Real world experience comparing neurologists and primary care physician management of acute migraine with almotriptan in Spain. Presented at the 56th Annual Meeting of the American Academy of Neurology. 24 April-1 May, San Francisco, USA. http://www.aan.com (Accessed 29 June 2004.)